© Drug Hunter Inc. 2018-2023
Home > Remibrutinib
BTK-selective covalent kinase inhibitor
Ph. I completed in HV, in Ph. II
SBDD from reversible BTK inhibitor and opt.
J. Med. Chem., Mar. 4, 2020
Novartis, Basel, CH
Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year